Is ozanimod effective for ulcerative colitis?

Ozamod (ozanimod) is the first sphingosine-1-phosphate receptor (S1PR) modulator approved in the United States for the treatment of adults with moderately to severely active ulcerative colitis. The oral formulation of ozanimod is administered once daily as induction and maintenance therapy.

In the randomized, double-blind, multinationalPhase 2 Touchstone and Phase 3 True North clinical trials, ozanimod was effective compared with placebo in inducing clinical remission and maintaining remission in adults with moderately to severely active ulcerative colitis. In these studies, Ozamod was generally well tolerated, with manageable or transient adverse events (AEs). Current data from the Touchstone and True North open-label extensions are consistent with preliminary studies on efficacy and tolerability, with no new safety signals observed. While further data will be beneficial, ozanimod expands treatment options for adults with moderately to severely active ulcerative colitis.

The original drug Ozamod has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.